Browsing Tag
Visus Therapeutics Inc.
1 post
Lupin adds Yuvezzi to €190m VISUfarma bet as European ophthalmology strategy takes shape
Lupin has secured exclusive Yuvezzi rights across major European markets through VISUfarma, extending its €190 million ophthalmology investment into a differentiated prescription therapy that still requires regional approvals.